Cargando…
T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
Autores principales: | Lynch, Ryan C., Alig, Stefan, Ujjani, Chaitra S., Poh, Christina, Warren, Edus H., Smith, Stephen D., Shadman, Mazyar, Shustov, Andrei, Till, Brian, Raghunathan, Vikram M., Tseng, Yolanda, Coye, Hilary, Shelby, Megan, Ottemiller, Susan, Keo, Sarith, Verni, Kaitlin, Du, Hongyan, Vandermeer, Jackie, Gaston, Ashley, Rasmussen, Heather, Gulhane, Avanti, Chen, Delphine L., Martin, Paul, Marzbani, Edmond, Voutsinas, Jenna, Alizadeh, Ash A., Gopal, Ajay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621540/ http://dx.doi.org/10.1097/01.HS9.0000890796.34979.cc |
Ejemplares similares
-
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022) -
Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021) -
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021) -
Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
por: Graf, Solomon A., et al.
Publicado: (2021) -
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)